BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alere Inc. (ALR) Recalls 803,000 Tests for Heart Attacks


5/24/2012 8:02:21 AM

Boston Business Journal by Julie M. Donnelly, Reporter

Alere Inc. (NYSE: ALR) has recalled 803,000 heart tests following a U.S.Food and Drug Administration inspection of its San Diego plant raised concerns over quality control processes. The company’s stock was down more than 3 percent in morning trading Wednesday, after the announcement.

The tests in question brought in revenue of $69 million in the first quarter.

Executives at the Waltham, Mass.-based company acknowledged the recall could cause shortages of the tests, and committed to ramp up production with new quality control standards.

“Alere anticipates that its efforts to increase production will lead to increased manufacturing costs, commencing in the second quarter of 2012,” company officials wrote in a regulatory filing, published Wednesday. The company said it does not yet know what impact the recall will have on earnings.

“I would say that the (annual earnings) per share impact will be somewhere between 15 cents and 35 cents,” Constantine Davides, a Boston-based analyst at JMP Securities, said. “The new process will likely mean that they can produce less product and it will cost them more to do it.” Davides says much depends on how many additional tests, if any, are recalled, and the company’s margins going forward.

Alere posted a diluted net income of 9 cents per share for the full year, 2011.

Alere disclosed in regulatory documents on May 10 that the FDA had concerns about the “quality control release method” for the company’s Triage products, which are rapid diagnostic test systems used to diagnose conditions including heart failure. On May 11, the company’s stock dropped almost 14 percent and has continued to slide since then.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES